Date: 2015-03-31
Type of information: Nomination
Compound:
Company: Tyrogenex (USA - Fl)
Therapeutic area: Cancer - Oncology - Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 31, 2015, Tyrogenex and Xcovery, two privately held companies focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, announced the appointment of Michael D. Webb as president and CEO of both companies. The boards of both companies appointed Webb, who has been CEO of four biotechnology companies as well as chairman of the MassBio industry organization, as president and CEO. Sheridan Snyder, co-founder and former president and CEO of both companies, remains chairman of the Xcovery board and a director on the Tyrogenex board. Tyrogenex and Xcovery share a common scientific legacy and management team. Xcovery is developing X-396, an anaplastic lymphoma kinase (ALK) inhibitor for non-small cell lung cancer entering phase 3 this year. Tyrogenex is developing X-82, an orally administered, dual VEGFR/PDGFR inhibitor for angiogenesis in oncology and wet age-related macular degeneration (AMD). Tyrogenex is planning to initiate a large phase 2 study of X-82 for both wet AMD and solid tumors in 2015. Michael D.Webb joins Tyrogenex and Xcovery with more than 25 years’ experience in growing biotechnology companies and a track record that includes raising more than $350 million in private and public equity markets. Most recently, he was president and CEO of Allegro Diagnostics Corp., a venture-backed, molecular diagnostics company focused on lung cancer that was acquired by Veracyte in 2014. Prior to that, he founded and served as president and CEO of Anchor Therapeutics, Inc. During his time as president and CEO of EPIX Pharmaceuticals, he led the company from “A”-round financing to an industry leadership position in pharmaceuticals for diagnostic imaging and listing on NASDAQ. Webb has served as chairman of the Massachusetts Biotechnology Council, founding chairman of the United Way of Massachusetts Bay’s Math, Science and Technology Initiative.
Financial terms:
Latest news:
